Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

334.11 +1.53 (+0.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,066,210
Open 333.52
Bid (Size) 328.69 (1)
Ask (Size) 338.85 (1)
Prev. Close 332.58
Today's Range 328.61 - 335.00
52wk Range 243.17 - 354.46
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 No-Brainer Stocks to Buy in June
These biopharma stocks could be big winners. 
Via The Motley Fool
Breakthrough in CRISPR-Based Therapy: FDA Accepts Vertex and CRISPR Therapeutics' Exa-cel Application
The FDA has accepted the application for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG (NASDAQ: CRSP) exa-cel for sickle cell disease and transfusion-dependent  
Via Benzinga

Performance

YTD
+16.81%
+16.81%
1 Month
-4.55%
-4.55%
3 Month
+16.32%
+16.32%
6 Month
+7.01%
+7.01%
1 Year
+28.65%
+28.65%

More News

Read More
Vertex/CRISPR Partnered Cell Therapy Shows Encouraging In Sickle Cell Disease, Thalassemia Patients
Via Benzinga
Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
$1000 Invested In This Stock 15 Years Ago Would Be Worth $10,000 Today
Via Benzinga
CRISPR Therapeutics: A Galaxy's Worth of Deep Value
Via The Motley Fool
Expert Ratings for Vertex Pharmaceuticals
Via Benzinga
Why Is CRISPR Therapeutics (CRSP) Stock Moving Today?
Via InvestorPlace
Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months
Via Investor's Business Daily
2 Top Biotech Stocks to Buy in June
Via The Motley Fool
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
5 Top Stocks to Buy in June
Via The Motley Fool
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Via The Motley Fool
A New S&P 500 Bull Market Is Nearly Here: 3 No-Brainer Stocks to Buy Sooner Rather Than Later
Via The Motley Fool
3 Top Healthcare Stocks to Buy for June
Via The Motley Fool
Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?
Via The Motley Fool
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade
Via The Motley Fool
Got $1,000? 2 Amazing Growth Stocks That Could Help You Retire Richer
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023
Via Benzinga
Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Wall Street Thinks This Stock Will Only Rise 12%: Here's Why It Could Jump a Lot More
Via The Motley Fool
Want to Get Richer? 3 Top Stocks to Buy Now and Hold Forever
Via The Motley Fool
The Best Stocks to Invest $20,000 in Right Now
Via The Motley Fool
2 Supercharged Stocks to Buy With $100
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.